SHARx calls for closer scrutiny of PBM contracts
As employers reconsider PBM relationships, SHARx warns switching vendors may not address the root incentives behind prescription drug costs.
SHARx
SHARx: TrumpRx platform exposes issues in drug pricing and access
SHARx argues that without tackling rebate-driven economics and PBM decision-making power, efforts to lower drug prices may have limited impact on patients.
As 2026 Rx price hikes begin, SHARx targets the specialty drug “Black Box”
As drugmakers implement 2026 price increases, SHARx argues that specialty pharmacy practices, not just list prices, often determine patient access and out-of-pocket costs.